Monosomal Karyotype in Acute Myeloid Leukemia: A Better Indicator of Poor Prognosis Than a Complex Karyotype
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Purpose: To investigate the prognostic value of various cytogenetic components of a complex karyotype in acute myeloid leukemia (AML). Patients and Methods: Cytogenetics and overall survival (OS) were analyzed in 1,975 AML patients age 15 to 60 years. Results: Besides AML with normal cytogenetics (CN) and core binding factor (CBF) abnormalities, we distinguished 733 patients with cytogenetic abnormalities. Among the latter subgroup, loss of a single chromosome (n = 109) conferred negative prognostic impact (4-year OS, 12%; poor outcome). Loss of chromosome 7 was most common, but outcome of AML patients with single monosomy −7 (n = 63; 4-year OS, 13%) and other single autosomal monosomies (n = 46; 4-year OS, 12%) did not differ. Structural chromosomal abnormalities influenced prognosis only in association with a single autosomal monosomy (4-year OS, 4% for very poor v 24% for poor). We derived a monosomal karyotype (MK) as a predictor for very poor prognosis of AML that refers to two or more distinct autosomal chromosome monosomies (n = 116; 4-year OS, 3%) or one single autosomal monosomy in the presence of structural abnormalities (n = 68; 4-year OS, 4%). In direct comparisons, MK provides significantly better prognostic prediction than the traditionally defined complex karyotype, which considers any three or more or five or more clonal cytogenetic abnormalities, and also than various individual specific cytogenetic abnormalities (eg, del[5q], inv[3]/t[3;3]) associated with very poor outcome. Conclusion: MK enables (in addition to CN and CBF) the prognostic classification of two new aggregates of cytogenetically abnormal AML, the unfavorable risk MK-negative category (4-year OS, 26% ± 2%) and the highly unfavorable risk MK-positive category (4-year OS, 4% ± 1%).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International System for Human Cytogenetic Nomenclature
National Cancer Institute (2020) · Definitions · doi:10.32388/78qroa · Cited by 6,840
Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,655
Slovak, M. L., Kopecky, K. J., Cassileth, P. A., Harrington, D. H., Theil, K. S., Mohamed, A., Paietta, E., Willman, C. L., Head, D. R., Rowe, J. M., et al. (2000) · Blood · doi:10.1182/blood.v96.13.4075 · Cited by 1,601
Byrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,597
Cytogenetics in acute leukemia
Mrózek, K., Heerema, N. A., & Bloomfield, C. D. (2004) · Blood Reviews · doi:10.1016/s0268-960x(03)00040-7 · Cited by 659
Wheatley, K., Burnett, A. K., Goldstone, A. H., Gray, R. G., Hann, I. M., Harrison, C. J., Rees, J. K. H., Stevens, R. F., & Walker, H. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01684.x · Cited by 434
Löwenberg, B., van Putten, W., Theobald, M., Gmür, J., Verdonck, L., Sonneveld, P., Fey, M., Schouten, H., de Greef, G., Ferrant, A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025406 · Cited by 386
Self-citationSchoch, C., Haferlach, T., Haase, D., Fonatsch, C., Löffler, H., Schlegelberger, B., Staib, P., Sauerland, M. C., Heinecke, A., Büchner, T., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02511.x · Cited by 178
Mrózek, K., & Bloomfield, C. D. (2006) · Hematology · doi:10.1182/asheducation-2006.1.169 · Cited by 141
Löwenberg, B., Boogaerts, M. A., Daenen, S. M., Verhoef, G. E., Hagenbeek, A., Vellenga, E., Ossenkoppele, G. J., Huijgens, P. C., Verdonck, L. F., van der Lelie, J., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.12.3496 · Cited by 126
Self-citation
Cited by
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Self-citationGenomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Self-citationGrimwade, D., Hills, R. K., Moorman, A. V., Walker, H., Chatters, S., Goldstone, A. H., Wheatley, K., Harrison, C. J., Burnett, A. K., & on behalf of the National Cancer Research Institute Adult Leukaemia Working Group (2010) · Blood · doi:10.1182/blood-2009-11-254441 · Cited by 1,938
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
Löwenberg, B., Ossenkoppele, G. J., van Putten, W., Schouten, H. C., Graux, C., Ferrant, A., Sonneveld, P., Maertens, J., Jongen-Lavrencic, M., von Lilienfeld-Toal, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901409 · Cited by 828
Self-citationWei, A. H., Strickland, S. A., Hou, J.-Z., Fiedler, W., Lin, T. L., Walter, R. B., Enjeti, A., Tiong, I. S., Savona, M., Lee, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01600 · Cited by 692
Rücker, F. G., Schlenk, R. F., Bullinger, L., Kayser, S., Teleanu, V., Kett, H., Habdank, M., Kugler, C.-M., Holzmann, K., Gaidzik, V. I., et al. (2012) · Blood · doi:10.1182/blood-2011-08-375758 · Cited by 683
Bernard, E., Nannya, Y., Hasserjian, R. P., Devlin, S. M., Tuechler, H., Medina-Martinez, J. S., Yoshizato, T., Shiozawa, Y., Saiki, R., Malcovati, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1008-z · Cited by 648
Creutzig, U., van den Heuvel-Eibrink, M. M., Gibson, B., Dworzak, M. N., Adachi, S., de Bont, E., Harbott, J., Hasle, H., Johnston, D., Kinoshita, A., et al. (2012) · Blood · doi:10.1182/blood-2012-03-362608 · Cited by 577
Genomics of Acute Myeloid Leukemia Diagnosis and Pathways
Bullinger, L., Döhner, K., & Döhner, H. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.2208 · Cited by 541
Kayser, S., Döhner, K., Krauter, J., Köhne, C.-H., Horst, H. A., Held, G., von Lilienfeld-Toal, M., Wilhelm, S., Kündgen, A., Götze, K., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301713 · Cited by 487
Wang, Y., Liu, Q.-F., Xu, L.-P., Liu, K.-Y., Zhang, X.-H., Ma, X., Fan, Z.-P., Wu, D.-P., & Huang, X.-J. (2015) · Blood · doi:10.1182/blood-2015-02-627786 · Cited by 486
Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance
Grimwade, D., Ivey, A., & Huntly, B. J. P. (2016) · Blood · doi:10.1182/blood-2015-07-604496 · Cited by 445
Cytarabine Dose for Acute Myeloid Leukemia
Löwenberg, B., Pabst, T., Vellenga, E., van Putten, W., Schouten, H. C., Graux, C., Ferrant, A., Sonneveld, P., Biemond, B. J., Gratwohl, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010222 · Cited by 407
Self-citationCornelissen, J. J., Gratwohl, A., Schlenk, R. F., Sierra, J., Bornhäuser, M., Juliusson, G., Råcil, Z., Rowe, J. M., Russell, N., Mohty, M., et al. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.150 · Cited by 400
Self-citationAbbas, S., Lugthart, S., Kavelaars, F. G., Schelen, A., Koenders, J. E., Zeilemaker, A., van Putten, W. J. L., Rijneveld, A. W., Löwenberg, B., & Valk, P. J. M. (2010) · Blood · doi:10.1182/blood-2009-11-250878 · Cited by 393
Self-citationO'Donnell, M. R., Abboud, C. N., Altman, J., Appelbaum, F. R., Arber, D. A., Attar, E., Borate, U., Coutre, S. E., Damon, L. E., Goorha, S., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0103 · Cited by 323
Kleppe, M., Koche, R., Zou, L., van Galen, P., Hill, C. E., Dong, L., De Groote, S., Papalexi, E., Hanasoge Somasundara, A. V., Cordner, K., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.11.009 · Cited by 279
Acute myeloid leukemia: 2013 update on risk‐stratification and management
Estey, E. H. (2013) · American Journal of Hematology · doi:10.1002/ajh.23404 · Cited by 277
Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia
Ribeiro, A. F. T., Pratcorona, M., Erpelinck-Verschueren, C., Rockova, V., Sanders, M., Abbas, S., Figueroa, M. E., Zeilemaker, A., Melnick, A., Löwenberg, B., et al. (2012) · Blood · doi:10.1182/blood-2011-07-367961 · Cited by 262
Self-citationfor the International Working Group for MDS Molecular Prognostic Committee, Haase, D., Stevenson, K. E., Neuberg, D., Maciejewski, J. P., Nazha, A., Sekeres, M. A., Ebert, B. L., Garcia-Manero, G., Haferlach, C., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0351-2 · Cited by 259
Chen, X., Xie, H., Wood, B. L., Walter, R. B., Pagel, J. M., Becker, P. S., Sandhu, V. K., Abkowitz, J. L., Appelbaum, F. R., & Estey, E. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3518 · Cited by 257
Lugthart, S., Gröschel, S., Beverloo, H. B., Kayser, S., Valk, P. J. M., van Zelderen-Bhola, S. L., Jan Ossenkoppele, G., Vellenga, E., van den Berg-de Ruiter, E., Schanz, U., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.2771 · Cited by 256
Self-citationLubbert, M., Ruter, B. H., Claus, R., Schmoor, C., Schmid, M., Germing, U., Kuendgen, A., Rethwisch, V., Ganser, A., Platzbecker, U., et al. (2012) · Haematologica · doi:10.3324/haematol.2011.048231 · Cited by 230
“Bone marrow blasts (%) median (range) 56 (10-100) < 30 – n.”
Self-citationHow I treat the older patient with acute myeloid leukemia
Ossenkoppele, G., & Löwenberg, B. (2015) · Blood · doi:10.1182/blood-2014-08-551499 · Cited by 202
Self-citationIndependent prognostic factors for AML outcome
Grimwade, D., & Hills, R. K. (2009) · Hematology · doi:10.1182/asheducation-2009.1.385 · Cited by 180
Della Porta, M. G., Alessandrino, E. P., Bacigalupo, A., van Lint, M. T., Malcovati, L., Pascutto, C., Falda, M., Bernardi, M., Onida, F., Guidi, S., et al. (2014) · Blood · doi:10.1182/blood-2013-12-542720 · Cited by 179
“Complete remission — — 41% (27-58) 23% (12-43) .”
InfluentialInterconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia
McKenzie, M. D., Ghisi, M., Oxley, E. P., Ngo, S., Cimmino, L., Esnault, C., Liu, R., Salmon, J. M., Bell, C. C., Ahmed, N., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.07.001 · Cited by 91
Duhoux, F. P., Ameye, G., Montano‐Almendras, C. P., Bahloula, K., Mozziconacci, M. J., Laibe, S., Wlodarska, I., Michaux, L., Talmant, P., Richebourg, S., et al. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08918.x · Cited by 56
Metadata
- Authors
- Breems, D. A., Van Putten, W. L. J., De Greef, G. E., Van Zelderen-Bhola, S. L., Gerssen-Schoorl, K. B. J., Mellink, C. H. M., Nieuwint, A., Jotterand, M., Hagemeijer, A., Beverloo, H. B., & Löwenberg, B.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-10-10
- Volume
- 26
- Issue
- 29
- Pages
- 4791-4797
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2117446917
- Cited by
- 580
- References
- 13
- FWCI
- 20.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.